A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

Abstract Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among all infants worldwide and remains a significant cause of morbidity and mortality. To address this unmet medical need, MK‐1654, a half‐life extended RSV neutralizing monoclonal antibody, is in c...

Full description

Bibliographic Details
Main Authors: Yuji Orito, Naoyuki Otani, Yuki Matsumoto, Katsukuni Fujimoto, Nobuyuki Oshima, Brian M. Maas, Luzelena Caro, Antonios O. Aliprantis, Kara S. Cox, Osamu Tokumaru, Masaaki Kodama, Hideo Kudo, Hiromitsu Imai, Naoto Uemura
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13290

Internet

https://doi.org/10.1111/cts.13290

Similar Items